Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials

Thura W. Htut* (Corresponding Author), Kyaw Z. Thein, Alastair Lawrie, Jane Tighe, Gavin Preston

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Abstract The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta-analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regimens. The relative risk for progression was significantly lower in daratumumab-treated cohorts (HR 0.46, 95% CI 0.38-0.55) and this was consistent across newly diagnosed and relapsed cases. No statistically significant improvement was identified in newly diagnosed patients with high-risk cytogenetics and this group remains a therapeutic challenge.
Original languageEnglish
JournaleJHaem
Early online date23 Jun 2020
DOIs
Publication statusE-pub ahead of print - 23 Jun 2020

Keywords

  • daratumumab
  • meta-analysis
  • multiple myeloma
  • phase III randomized controlled trials

Fingerprint Dive into the research topics of 'Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials'. Together they form a unique fingerprint.

  • Cite this